SciClone Pharmaceuticals to Present at Two Investor Conferences in November
* Reuters is not responsible for the content in this press release.
FOSTER CITY, CA, Nov 10 (MARKET WIRE) --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
will present at two upcoming investor conferences: Lazard Capital Markets
Healthcare Conference and Piper Jaffray Health Care Conference. Friedhelm
Blobel, Ph.D., SciClone's President and Chief Executive Officer, will
present a corporate overview and business update at each conference.
Lazard Capital Markets Healthcare
Tuesday, November 16; 2:40 pm ET
New
York City, NY
Piper Jaffray Health Care Conference
Tuesday, November 30; 12:30 pm ET
New York City, NY
To access the live audio webcasts of the presentations, please log on
through a link located in the Investor Relations section of SciClone's
website at www.sciclone.com.
About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a
revenue-generating, China-centric, specialty pharmaceutical company with
a substantial international business and a product portfolio of novel
therapies for cancer and infectious diseases. The Company is focused on
continuing sales growth and executing a clinical development strategy
with prudently managed costs. ZADAXIN(R) (thymalfasin) is approved in
over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C
(HCV), certain cancers, and as a vaccine adjuvant. In addition to further
studying thymalfasin's use as a vaccine enhancer, SciClone is planning to
evaluate SCV-07 in a phase 2b trial to modify the course of oral
mucositis in patients with head and neck cancer; and is evaluating SCV-07
in a phase 2b trial for the treatment of HCV. The Company also has
exclusive commercialization and distribution rights in China to a novel
treatment for advanced liver cancer, DC Bead(R), currently under review
by regulatory agencies in that country. Additionally, SciClone owns
exclusive commercialization and distribution rights to the anti-nausea
drug ondansetron RapidFilm(R) in China, including Hong Kong and Macau,
and Vietnam. The Company intends to seek regulatory approval for the
product, commonly used to treat and prevent nausea and vomiting caused by
chemotherapy, radiotherapy, and surgery, in these markets. For additional
information, please visit www.sciclone.com.
DC Bead is a registered trademark of Biocompatibles UK Limited.
RapidFilm is a registered trademark of Labtec Gesellschaft fuer
technologische Forschung und Entwicklung mbH.
Contact
Ana Kapor
Investors/Media
650.350.4825
akapor@sciclone.com
Copyright 2010, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters